Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX) has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for USD 1.65 billion upfront plus up to USD 700 million in contingent consideration tied to regulatory approvals and commercial milestones for ITM's lead therapeutic candidate, in a deal that allows Telix to internalize much of the radioisotope supply chain supporting its therapeutic pipeline.
The upfront consideration will be paid primarily in Telix shares — 105.8 million shares valued at USD 1.25 billion — with Telix also assuming USD 302 million of ITM's net debt at closing.
The contingent USD 700 million is structured in two tranches: up to USD 250 million linked to FDA approvals of ITM-11 (¹⁷⁷Lu-edotreotide), a lutetium-177-labeled somatostatin receptor-targeted therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), across three indications by specified deadlines through 2031; and up to USD 450 million based on ITM-11 net global sales. Upon closing, Telix shareholders will hold approximately 76.3% of the combined entity.
ITM, founded in 2004 and headquartered in Munich, operates commercial-scale manufacturing of lutetium-177 (¹⁷⁷Lu), actinium-225 (²²⁵Ac), and terbium-161 (¹⁶¹Tb), with a global distribution network spanning more than 65 countries. The company reported audited revenue of USD 273 million in 2025, representing a compound annual growth rate of 40% from 2021 to 2025. Its isotope manufacturing business is profitable and cash-generative, and the combined organization is expected to generate pro forma 2026 revenue and income exceeding USD 1.3 billion, with Telix targeting positive EBITDA contribution from 2027 onward, subject to synergy realization.
The clinical asset at the center of the contingent structure, ITM-11, completed the Phase III COMPETE trial (NCT03049189), with results published in The Lancet in July 2026. A second Phase III study, COMPOSE (NCT04919226), targeting an indication expansion, is fully enrolled with an interim analysis expected in H1 2027. ITM-11 received an FDA Complete Response Letter in August 2026 citing chemistry, manufacturing, and controls issues and third-party commercial facility inspection items, with no concerns raised about the clinical data package. The CRL's manufacturing-specific nature is directly relevant to the rationale for the transaction: Telix, which acquired IsoTherapeutics Group in February 2024 to expand its US manufacturing infrastructure, said it intends to resubmit the ITM-11 NDA.